Details for Patent: 7,776,838

Which drugs does patent 7,776,838 protect, and when does it expire?

Patent 7,776,838 protects VISTOGARD and is included in one NDA.

This patent has one hundred and seventy-five patent family members in twenty-one countries.

Summary for Patent: 7,776,838

Title:	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
Abstract:	The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.
Inventor(s):	von Borstel; Reid W. (Potomac, MD), Bamat; Michael K. (Potomac, MD)
Assignee:	Wellstat Therapeutics Corporation (Gaithersburg, MD)
Application Number:	08/460,186
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 7,776,838

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Btg Intl	VISTOGARD	uridine triacetate	GRANULE;ORAL	208159-001	Dec 11, 2015		RX	Yes	Yes						EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS

International Family Members for US Patent 7,776,838

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	142221
Austria	179615
Austria	205850
Austria	243039